Sym004 in Patients With Advanced Solid Tumors

Status:
Completed

Trial end date:
2015-05-01

Target enrollment:

Participant gender:

This trial is designed as a multi-centre, open label, dose-escalation, phase I trial and consists of five parts.

Phase 1/Phase 2

Symphogen A/S